GEN Exclusives

More »

GEN News Highlights

More »
Aug 17, 2007

Mechanism of Treg Recruitment in Cancer Revealed

  • Cancers cells in animal models use indoleamine 2,3-dioxygenase (IDO), an enzyme used by fetuses to help avoid rejection, to recruit Treg cells that turn down the immune response, report scientists at the Medical College of Georgia Cancer Center.

    The study found that IDO, which seems to play a role in tumor survival despite the relatively few number of cells in the tumor’s draining lymph nodes, directly activates existing Tregs that become strongly suppressive within a day. This rapid conversion occurs only in lymph nodes connected to tumors.

    The researchers also discovered that the Tregs then up-regulate the PD-L1/PD-L2 pathway, which has been shown to play an important role in the immune suppression caused by AIDS.

    The study was published online in the August 16 issue of The Journal of Clinical Investigation.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?